Enabling More Precise Monitoring for Blood Cancer Patients
Pairidex is developing a more accurate, personalized platform for monitoring blood cancers, enabling clinicians to make better-informed treatment decisions over time. The company’s rapid and cost-effective test leverages droplet digital PCR (ddPCR) to detect the unique genomic alterations driving an individual patient’s cancer.
By providing highly sensitive measurements of disease burden, Pairidex enables clinicians to track cancer progression and response to treatment with greater precision over time. This personalized approach supports more informed treatment decisions and ongoing patient management.
Pairidex Highlights
Since its founding, Pairidex has made strong progress in building both its technology platform and operational foundation. The company was established in 2023 by Washington University physician-scientist and CSO Dr. Andrew Young, MD, PhD, and is led by CEO Paul Kortschak, MBA, JD.
In 2024, Pairidex closed an oversubscribed pre-seed funding round, enabling the company to formally launch operations and accelerate development. Its clinically validated assay has demonstrated the ability to reliably detect disease at extremely low levels—down to 1 cancer cell in 100,000 cells—highlighting its potential for highly sensitive monitoring.
To support clinical deployment, Pairidex successfully established a CAP-accredited, CLIA-certified laboratory, operated by a strong and growing team of scientists. By 2025, the company had expanded its platform of assays and begun working with multiple customers and collaborators, further validating its approach and market need.
BioGenerator’s Role in Pairidex’s Launch and Growth
Pairidex was co-founded by BioGenerator and continues to operate within the BioGenerator Labs, benefiting from early access to infrastructure and resources. BioGenerator led the company’s pre-seed funding round in 2024, providing critical early capital to launch and scale operations.
In addition to investment, BioGenerator delivered non-dilutive support for clinical laboratory development, regulatory consulting, and grant writing—helping Pairidex navigate complex early-stage challenges. BioGenerator Principal Allyson Mayer, PhD, also serves as the company’s interim COO, providing hands-on operational leadership during a key phase of growth.
Through this combination of capital, expertise, and hands-on support, BioGenerator has played an integral role in shaping Pairidex from concept through early development and growth.
“BioGenerator was the first external supporter of Pairidex, even before we had a name. Together, we founded the company, built a business model, raised funds, and developed the team. BioGenerator has been instrumental at every stage of our growth.”
Andrew Young, MD, PhD, Founder & CSO, Pairidex
Watch at